Current targeted therapeutics against COVID-19: Based on first-line experience in China
Documentos PDF
Imagenes y Videos
Abstract
SARS-CoV-2 is a novel strain, causing a global pandemic since the end of 2019. The majority of patients showed
nonspecific symptoms such as fever, dry cough, and fatigue. Most patients have a good prognosis while some
with severe conditions could rapidly progress to acute respiratory distress syndrome, septic shock, metabolic
acidosis, coagulation dysfunction, and even die. The exacerbation of the patient's condition may be due to a
cytokine storm in the body. Effective targeted therapies including antiviral and immunization are urgently
needed. Although many clinical trials are already underway and the majority of patients have received antiviral
therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven
to be effective currently. We summarize the current therapeutic medicines used in the clinic, hope to be able to
provide some implications for clinical medication.
Palabras clave
COVID-19; Therapy; Antiviral; ImmunizationLink to resource
https://doi.org/10.1016/j.phrs.2020.104854Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.